0 reactions
indianmarketgrid Novo Nordisk said its next-generation obesity candidate outperformed Eli Lilly’s rival in a late-stage study of people with diabetes.
READ FULL ANALYSIS MEMBER ANALYSIS
THE IMG COMMUNITY
Market insights. Fresh perspectives. Your conversation.
indianmarketgrid Novo Nordisk said its next-generation obesity candidate outperformed Eli Lilly’s rival in a late-stage study of people with diabetes.